Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

C A Uyl-de Groot

Biographic Data

ID10435719
NAMEC A Uyl-de Groot
GIVEN NAMESC A Uyl
FAMILY NAMEde Groot
SIGNATUREDE GROOT C A U
VERIFIEDNo
TOTAL WORKS2
TOTAL CITATIONS0
WORKS AS AUTHOR2
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2015
LATEST PUBLICATION YEAR2017
H-INDEX0
  • Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma

    Open Access•Saskia de Groot, W K Redekop et al.•ARTICLE•Quality of Life Research•2017

    Key drivers for reduced HRQoL in mRCC are disease symptoms. Since symptoms increase with progression of disease, targeted therapies that increase PFS are expected to postpone reductions in HRQoL in mRCC

  • Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands

    Open Access•Kim Holtzer-Goor, K M Holtzer-Goor et al.•ARTICLE•Quality of Life Research•2015

    CLL patients differ most from the general population on role functioning, fatigue, concerns about future health, and having not enough energy. Once treatment is indicated, HRQoL becomes considerably compromised. This applies to all treatments, including chlorambucil, which is considered to be a mild treatment

No prominent works on this page.

  • Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands

    Open Access•Kim Holtzer-Goor, K M Holtzer-Goor et al.•ARTICLE•Quality of Life Research•2015

    CLL patients differ most from the general population on role functioning, fatigue, concerns about future health, and having not enough energy. Once treatment is indicated, HRQoL becomes considerably compromised. This applies to all treatments, including chlorambucil, which is considered to be a mild treatment

  • Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma

    Open Access•Saskia de Groot, W K Redekop et al.•ARTICLE•Quality of Life Research•2017

    Key drivers for reduced HRQoL in mRCC are disease symptoms. Since symptoms increase with progression of disease, targeted therapies that increase PFS are expected to postpone reductions in HRQoL in mRCC

Disease (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Physical therapy (2 works) · Quality of life (healthcare (2 works) · Apathy (1 work) · Bladder and Urothelial Cancer Treatments (1 work) · Cancer (1 work) · Chemotherapy (1 work) · Childhood Cancer Survivors' Quality of Life (1 work)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae